Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Trk inhibitor

DRUG CLASS:

Trk inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Biliary Tract Cancer	NTRK3 fusion	Biliary Tract Cancer	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2
NTRK2 fusion	Biliary Tract Cancer	NTRK2 fusion	Biliary Tract Cancer	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2
NTRK1 fusion	Biliary Tract Cancer	NTRK1 fusion	Biliary Tract Cancer	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1